PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs MYGN |
|---|---|---|---|---|---|
| INCY | Incyte Corporation | 0.25 | 15.7 | 62.7% | — |
| QGEN | Qiagen N.V. | 0.49 | 21.5 | 44.0% | — |
| UTHR | United Therapeutics Corporation | 0.87 | 18.2 | 20.9% | — |
| NBIX | Neurocrine Biosciences, Inc. | 11.69 | 22.7 | 1.9% | — |